RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced it will hold a business update call on Thursday, April 10, 2008 at 1:00 p.m. EDT. Dr. Mark Sirgo., President and Chief Executive Officer, will provide a brief update on the ongoing NDA review of the company’s lead product BEMA™ Fentanyl for the treatment of breakthrough cancer pain in opioid tolerant patients, along with other important corporate activities.
